|
NIH State of the Science Symposium on Myelodysplastic Syndromes (MDS)
Agenda
Wednesday, September 7, 2011
| 7:00 - 5:00 p.m. |
Registration
|
| 8:00 a.m. |
Introductions and Opening Remarks
|
| |
Susan B. Shurin, M.D.
Acting Director, NHLBI
Hal E. Broxmeyer, Ph.D.
Indiana University School of Medicine
|
| 8:20 a.m. |
Plenary Talk
MDS: What Have We Achieved in the Last Ten Years?
Pierre Fenaux, M.D., Ph.D.
Höpital Avicenne University (France)
|
| 8:50 a.m. |
Session I: Scientific and Clinical Challenges
|
| |
Overview and Scientific Challenges and Questions
Cheryl L. Willman, M.D
University of New Mexico Cancer Research and Treatment Center
Prognostic and Predictive Markers of Tomorrow
Eva Hellstrom-Lindberg, M.D., Ph.D.
Karolinska Institutet (Sweden)
Clinical Challenges and Questions
Guillermo Garcia-Manero, M.D.
MD Anderson Cancer Center
|
| |
Roundtable Discussion
Break
|
| 11:00 a.m. |
Session II: Biology and Pathophysiology
Overview
Benjamin L. Ebert, M.D., Ph.D.
Brigham and Women's Hospital
Microenvironment in the Regulation of Normal and
MDS Stem Cells
David T. Scadden, M.D.
Massachusetts General Hospital / Harvard Stem Cell Institute
Genetic Lesions that Phenocopy Dysplasia and Progression
to AML
Peter D. Aplan, M.D.
National Cancer Institute
Bone Marrow Failure Syndromes and MDS
Monica Bessler, M.D., Ph.D.
University of Pennsylvania
Roundtable Discussion
|
| 12:45 p.m. |
Lunch
|
| 1:30 p.m. |
Session III: MDS Genomics
Overview
Timothy Graubert, M.D.
Washington University in St. Louis
Inherited Predisposition to MDS: Syndromic, Familial, and
Sporadic Mutations
Marshall S. Horwitz, M.D., Ph.D.
University of Washington
Mutation Discovery in MDS Using Next-generation Sequencing
Mathew J. Walter, M.D.
Washington University in St. Louis
Biological Consequences of Mutations in the 5q Commonly
Deleted Interval
Benjamin L. Ebert, M.D., Ph.D.
Brigham and Women's Hospital
Roundtable Discussion
Break
|
| 3:35 p.m. |
Session IV: MDS Epigenomics
Overview
Jaroslaw P. Maciejewski, M.D., Ph.D.
Cleveland Clinic
MDS Methylome and Array-based Screens
Ari M. Melnick, M.D.
Weill Cornell Medical College
Genetic Drivers of Aberrant DNA Methylation and
Demethylation in MDS
Jaroslaw P. Maciejewski, M.D., Ph.D.
Cleveland Clinic
Characterization of Abnormal Histone Modification and
Genetic
Drivers in MDS
James G. Herman, M.D.
John Hopkins University
Roundtable Discussion
|
| 6:00 p.m. |
Adjourn
|
Thursday, September 8, 2011
| 8:00 - 9:30 a.m. |
Session V: Improved Therapeutic Outcomes
Overview
Eva Hellstrom-Lindberg, M.D., Ph.D.
Karolinska Institutet (Sweden)
MDS Stem Cells and Therapies: Enhancing Cure
Rate-biomarkers for
Resistant Disease and Risk of Relapse
Sten Erik W. Jacobsen, M.D., Ph.D.
University of Oxford (UNITED KINGDOM)
High Risk Disease and Relapse: Prospects of Epigenetic
Therapy
Steven D. Gore, M.D.
Johns Hopkins University
Low-risk MDS and Anemia: Biomarkers for Selecting Optimal
Treatment
for Cytopenia
Stephen D. Nimer, M.D.
Memorial Sloan-Kettering Cancer Center
Roundtable Discussion
|
| |
Session VI: Summary and Discussion
Pierre Fenaux, M.D., Ph.D.
Hôpital Avicenne University (France)
Hal E. Broxmeyer, Ph.D.
Indiana School of Medicine
|
| Noon |
Adjournment
|
Last Updated January 2012
|
Get Email Alerts
Twitter
Facebook
YouTube
Google+